Biophytis to Attend Key Upcoming Investor Events and Industry Conferences

Rhea-AI Summary

Biophytis SA (NasdaqCM: BPTS) announced its participation in several upcoming investor events, focusing on age-related therapeutics and severe respiratory failure treatments. Key events include the H. C. Wainwright 23rd Annual Global Investment Conference from September 13-15 (virtual), the Amsterdam MidCap Event from September 20-21 (virtual), and more through October and December. The company is advancing Sarconeos (BIO101) in Phase 2 clinical trials aimed at sarcopenia and COVID-19 respiratory distress. Biophytis operates out of Paris and Cambridge and trades on Nasdaq and Euronext Growth.

PARIS and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces its management will participate and meet with investors at the following upcoming events and conferences:

• H. C. Wainwright 23^rd Annual Global Investment Conference
  September 13 to 15 - Virtual

• Amsterdam MidCap Event
  September 20 to 21 - Virtual
  

• Investor Access Event
  September 27 to 28 - Paris
  

• HealthTech Innovation Days
  October 4 to 5 - Paris
  

• European MidCap Event
  October 19 to 22
  

• Galien Medstartup 2021
  October 25 to 29 - New York

• Geneva MidCap Event
  December 1 to 2
  

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, in development for the treatment of sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied, in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com

Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2020 Annual Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
Investors@biophytis.com

Media contact Life Sci Advisors
Sophie Baumont
E: sophie@lifesciadvisors.com 
T: +33 6 27 74 74 49

FAQ

What events will Biophytis (BPTS) attend in September 2021?

Biophytis will participate in the H. C. Wainwright 23rd Annual Global Investment Conference from September 13-15 and the Amsterdam MidCap Event from September 20-21, both held virtually.

What is the significance of Sarconeos (BIO101) for Biophytis (BPTS)?

Sarconeos (BIO101) is Biophytis's leading drug candidate, currently in Phase 2 trials aimed at treating sarcopenia and severe COVID-19 respiratory issues.

What other events is Biophytis (BPTS) participating in after September 2021?

After September, Biophytis will engage in the Investor Access Event from September 27-28 in Paris, HealthTech Innovation Days on October 4-5 in Paris, and the European MidCap Event from October 19-22.

Where is Biophytis (BPTS) based?

Biophytis is based in Paris, France, and Cambridge, Massachusetts.

What does Biophytis (BPTS) focus on in its research?

Biophytis focuses on developing therapeutics to slow aging processes and improve outcomes in age-related diseases, including treatments for severe respiratory failure in COVID-19 patients.